3.70
price down icon2.37%   -0.09
pre-market  시장 영업 전:  3.70  
loading
전일 마감가:
$3.79
열려 있는:
$3.75
하루 거래량:
2,564
Relative Volume:
0.08
시가총액:
$3.25M
수익:
$61,000
순이익/손실:
$-5.46M
주가수익비율:
-0.5657
EPS:
-6.54
순현금흐름:
$-6.76M
1주 성능:
-0.80%
1개월 성능:
-3.90%
6개월 성능:
-4.00%
1년 성능:
-46.92%
1일 변동 폭
Value
$3.70
$4.11
1주일 범위
Value
$3.53
$4.11
52주 변동 폭
Value
$3.03
$14.80

타이탄 파마슈티컬스 Stock (TTNP) Company Profile

Name
명칭
Titan Pharmaceuticals Inc De
Name
전화
(650) 244-4990
Name
주소
400 OYSTER POINT BLVD, SAN FRANCISCO
Name
직원
4
Name
트위터
@titanpharma
Name
다음 수익 날짜
2024-06-28
Name
최신 SEC 제출 서류
Name
TTNP's Discussions on Twitter

TTNP을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
TTNP
Titan Pharmaceuticals Inc De
3.70 3.25M 61,000 -5.46M -6.76M -6.54
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

타이탄 파마슈티컬스 Stock (TTNP) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2019-06-26 개시 Maxim Group Buy
2017-11-10 다운그레이드 ROTH Capital Buy → Neutral

타이탄 파마슈티컬스 주식(TTNP)의 최신 뉴스

pulisher
Apr 24, 2025

Nordic Pharma Enters $20.8M Eye Medicine Market with Generic Maxitrol Launch via Harrow Partnership - Stock Titan

Apr 24, 2025
pulisher
Apr 14, 2025

US Stocks Likely To Open Higher: Expert Says 'The Selling Pressure Is Starting To Be Exhausted' - Benzinga

Apr 14, 2025
pulisher
Apr 11, 2025

Titan Pharma Lands Crucial $1M Backing: Inside the Strategic Investment Deal - Stock Titan

Apr 11, 2025
pulisher
Apr 11, 2025

Clinical Data: Nika's ITV-1 Drug Demonstrates Breakthrough Effects in Multiple Diseases - Stock Titan

Apr 11, 2025
pulisher
Apr 10, 2025

Conduit Pharma Signals Stock Undervalued: Announces $1M Buyback as Phase II Trials Near - Stock Titan

Apr 10, 2025
pulisher
Apr 09, 2025

Strategic Board Shake-Up: Ex-Pharma CFO and Former Congressman Join Titan Environmental's Expansion Push - Stock Titan

Apr 09, 2025
pulisher
Apr 08, 2025

Failed Merger Forces Vincerx Pharma to Begin Company Wind-Down: What's Next for Investors? - Stock Titan

Apr 08, 2025
pulisher
Apr 04, 2025

Arrowhead Pharmaceuticals Expands Team with 34,190 RSU Grants to New Hires - Stock Titan

Apr 04, 2025
pulisher
Apr 04, 2025

Rigel Strengthens Biotech Team: Strategic Stock Grants Attract Key Talent - Stock Titan

Apr 04, 2025
pulisher
Apr 03, 2025

Strategic $2.5M Investment Values Mental Health Clinic Network at $50M: Major Expansion Ahead - Stock Titan

Apr 03, 2025
pulisher
Apr 02, 2025

Key Investor Update: Lexicon Pharma Takes Stage at Elite Needham Healthcare Conference - Stock Titan

Apr 02, 2025
pulisher
Apr 01, 2025

Citius Secures Strategic $2M Funding to Accelerate LYMPHIR LaunchKey Details Revealed - Stock Titan

Apr 01, 2025
pulisher
Mar 31, 2025

NRx Pharmaceuticals Lands Revenue-Generating Mental Health Clinic in Strategic Veterans Care Push - Stock Titan

Mar 31, 2025
pulisher
Mar 27, 2025

Ironwood Pharma Gets 60-Day Window to Resolve Nasdaq Compliance Issue - Stock Titan

Mar 27, 2025
pulisher
Mar 26, 2025

Actinium Reveals 3 Breakthrough Programs Targeting Billion-Dollar Markets at Mar-a-Lago Update - Stock Titan

Mar 26, 2025
pulisher
Mar 25, 2025

Actinium Expands into $B Market: Expert Reveals Breakthrough Cancer Programs - Stock Titan

Mar 25, 2025
pulisher
Mar 23, 2025

$10M Capital Raise: TransCode Therapeutics Accelerates TTX-MC138 Clinical Trials - StockTitan

Mar 23, 2025
pulisher
Mar 21, 2025

Titan Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post

Mar 21, 2025
pulisher
Mar 20, 2025

Major Shake-up: Universe Pharmaceuticals Announces 40:1 Share ConsolidationWhat It Means For Investors - StockTitan

Mar 20, 2025
pulisher
Mar 20, 2025

Plus Therapeutics Scores FDA Recognition for REYOBIQ Cancer DrugMajor Milestone for CNS Treatment - Stock Titan

Mar 20, 2025
pulisher
Mar 19, 2025

Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan

Mar 19, 2025
pulisher
Mar 13, 2025

Shuttle Pharma Raises $5.75M: Strategic Boost for Revolutionary Cancer Treatment Trial - Stock Titan

Mar 13, 2025
pulisher
Mar 12, 2025

NRx Pharmaceuticals Readies Major Financial Update: Full Year Results and Strategic Outlook Coming March 17 - Stock Titan

Mar 12, 2025
pulisher
Mar 11, 2025

Endo's $99M Strategic Sale: International Pharma Division Goes to Knight Therapeutics - Stock Titan

Mar 11, 2025
pulisher
Mar 10, 2025

Acurx Raises $1.1M in Direct Offering to Advance Antibiotics Pipeline - StockTitan

Mar 10, 2025
pulisher
Mar 07, 2025

Can This $1.1M Funding Keep Acurx's Antibiotic Development on Track? - StockTitan

Mar 07, 2025
pulisher
Mar 07, 2025

Will NovaBay Survive? Crucial Stockholder Vote Could Determine Company's Fate - StockTitan

Mar 07, 2025
pulisher
Mar 06, 2025

Can Conduit Pharmaceuticals Keep Its Nasdaq Listing? Critical Deadlines Ahead - Stock Titan

Mar 06, 2025
pulisher
Mar 05, 2025

How Will CTT Pharmaceuticals' OTCQB Upgrade Transform Its Market Presence? - StockTitan

Mar 05, 2025
pulisher
Mar 04, 2025

Milestone Pharmaceuticals Awards 94,000 Stock OptionsWhat This Means for Shareholder Value - Stock Titan

Mar 04, 2025
pulisher
Mar 03, 2025

Elite Pharmaceuticals Triples Manufacturing Potential With High-Speed Facility Launch - StockTitan

Mar 03, 2025
pulisher
Mar 03, 2025

When Will ARS Pharmaceuticals Reveal Its 2024 Financial Performance? - Stock Titan

Mar 03, 2025
pulisher
Feb 28, 2025

Is Vincerx Pharma Running Out of Options? Merger Deal Collapses as Cash Dwindles - Stock Titan

Feb 28, 2025
pulisher
Feb 27, 2025

Can Virpax's Breakthrough Drug Delivery Tech Transform Pain Management Without Opioid Risks? - StockTitan

Feb 27, 2025
pulisher
Feb 27, 2025

When Can Investors Hear Milestone Pharma's Next Strategic Update? Key Conference Date Revealed - Stock Titan

Feb 27, 2025
pulisher
Feb 26, 2025

Can This New Estée Lauder Partnership Transform How Your Skin Ages? - Stock Titan

Feb 26, 2025
pulisher
Feb 25, 2025

Will Universe Pharmaceuticals Survive Nasdaq's Latest Delisting Threat? - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

Adial's Addiction Treatment Clears Critical FDA Hurdle Ahead of 2025 Phase 3 Trials - Stock Titan

Feb 25, 2025
pulisher
Feb 24, 2025

Can KalVista's March Conference Circuit Signal Major Pipeline Updates? - Stock Titan

Feb 24, 2025
pulisher
Feb 21, 2025

Will SXTC's Share Consolidation Save Its Nasdaq Listing? Key Dates Revealed - StockTitan

Feb 21, 2025
pulisher
Feb 20, 2025

Can This $430M Pharma Merger Create the Next Women's Health Giant? - StockTitan

Feb 20, 2025
pulisher
Feb 20, 2025

Can This 1-for-5 Reverse Split Save 60 Degrees Pharma's Nasdaq Status? - StockTitan

Feb 20, 2025
pulisher
Feb 20, 2025

Failed Merger: Why HOOKIPA Pharma Walked Away from Poolbeg Deal - Stock Titan

Feb 20, 2025
pulisher
Feb 19, 2025

Can CNS Pharmaceuticals' 5 Key Growth Drivers Transform Brain Cancer Treatment? CEO Reveals 2025 Roadmap - Stock Titan

Feb 19, 2025
pulisher
Feb 18, 2025

Major Capital Raise: Petros Pharmaceuticals Locks $9.6M Financing DealStrategic Move or Dilution Risk? - Stock Titan

Feb 18, 2025
pulisher
Feb 14, 2025

Citius Pharmaceuticals Secures Critical J-Code for LYMPHIR as Cash Reserves Hit $1.1M - StockTitan

Feb 14, 2025
pulisher
Feb 13, 2025

Elite Pharma Q3 Results Reveal Sharp Profit Decline: Holiday Delays Impact Performance - StockTitan

Feb 13, 2025
pulisher
Feb 13, 2025

Major Lupus Breakthrough? Conduit Teams Up with Charles River for Game-Changing Treatment Study - Stock Titan

Feb 13, 2025
pulisher
Feb 11, 2025

Milestone's CARDAMYST Launch Roadmap: Key Details Coming for $1B PSVT Market Opportunity - Stock Titan

Feb 11, 2025
pulisher
Feb 10, 2025

Elite Pharmaceuticals (ELTP) Earnings Preview: Q3 Performance & Strategic Roadmap Unveiling Feb 14 - StockTitan

Feb 10, 2025
pulisher
Feb 10, 2025

Opioid Use Disorders Market to Reach USD 8.8 Billion by - GlobeNewswire

Feb 10, 2025

타이탄 파마슈티컬스 (TTNP) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
자본화:     |  볼륨(24시간):